High-mobility group box 1 (HMGB1) is elevated systemically in persons with acute or chronic traumatic spinal cord injury

Journal of Neurotrauma

Volumn 34, Issue 3, 2017, Pages 746-754

  Papatheodorou, Angelos ^a   Stein, Adam ^a   Bank, Matthew ^a   Sison, Cristina P ^a   Gibbs, Katie ^a   Davies, Peter ^b   Bloom, Ona ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

damage associated molecular pattern; high mobility group box 1; inflammation; spinal cord injury

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; STEROID; BIOLOGICAL MARKER; HMGB1 PROTEIN, HUMAN;

ACUTE SPINAL CORD INJURY; ADULT; AGED; ARTICLE; CHRONIC SPINAL CORD INJURY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NERVOUS SYSTEM INFLAMMATION; PROTEIN BLOOD LEVEL; SPINAL CORD INJURY; VERY ELDERLY; YOUNG ADULT; ACUTE DISEASE; BLOOD; CERVICAL VERTEBRA; CHRONIC DISEASE; THORACIC VERTEBRA;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CERVICAL VERTEBRAE; CHRONIC DISEASE; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; SPINAL CORD INJURIES; THORACIC VERTEBRAE; YOUNG ADULT;

EID: 85010796578     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2016.4596     Document Type: Article

References (56)

1. National Spinal Cord Injury Statistical Center. (2016). Spinal Cord Injury (SCI) Facts, and Figures at a Glance. University of Alabama: Birmingham
2. Schwab, J.M., Zhang, Y., Kopp, M.A., Brommer, B., and Popovich, P.G. (2014). The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury. Exp. Neurol. 258, 121-129
3. Kwon, B.K., Stammers, A.M., Belanger, L.M., Bernardo, A., Chan, D., Bishop, C.M., Slobogean, G.P., Zhang, H., Umedaly, H., Giffin, M., Street, J., Boyd, M.C., Paquette, S.J., Fisher, C.G., and Dvorak, M.F. (2010). Cerebrospinal fluid inflammatory cytokines, and biomarkers of injury severity in acute human spinal cord injury. J. Neurotrauma 27, 669-682
4. Kwon, B.K., Casha, S., Hurlbert, R.J., and Yong, V.W. (2011). Inflammatory, and structural biomarkers in acute traumatic spinal cord injury. Clin. Chem. Lab. Med. 49, 425-433
5. Pouw, M.H., Kwon, B.K., Verbeek, M.M., Vos, P.E., van Kampen, A., Fisher, C.G., Street, J., Paquette, S.J., Dvorak, M.F., Boyd, M.C., Hosman, A.J., and van De Meent, H. (2014). Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects. Spinal Cord 52, 428-433
6. Bank, M., Stein, A., Sison, C., Glazer, A., Jassal, N., McCarthy, D., Shatzer, M., Hahn, B., Chugh, R., Davies, P., and Bloom, O. (2015). Elevated circulating levels of the pro-inflammatory cytokine macrophage migration inhibitory factor in individuals with acute spinal cord injury. Arch. Phys. Med. Rehabil. 96, 633-644
7. Saltzman, J.W., Battaglino, R., Salles, L., Jha, P., Sudhakar, S., Garshick, E., Stott, H.L., Zafonte, R., and Morse, L.R. (2012). B-cell maturation antigen, a proliferation-inducing ligand, and B-cell activating factor are candidate mediators of spinal cord injury-induced autoimmunity. J. Neurotrauma 30, 434-440
8. Hayes, K.C., Hull, T.C., Delaney, G.A., Potter, P.J., Sequeira, K.A., Campbell, K., and Popovich, P.G. (2002). Elevated serum titers of proinflammatory cytokines, and CNS autoantibodies in patients with chronic spinal cord injury. J. Neurotrauma 19, 753-761
9. Stein, A., Panjwani, A., Sison, C., Rosen, L., Chugh, R., Metz, C., Bank, M., and Bloom, O. (2013). Pilot study: elevated circulating levels of the proinflammatory cytokine macrophage migration inhibitory factor in patients with chronic spinal cord injury. Arch. Phys. Med. Rehabil. 94, 1498-1507
10. Segal, J.L., Gonzales, E., Yousefi, S., Jamshidipour, L., and Brunnemann, S.R. (1997). Circulating levels of IL-2R, ICAM-1, and IL-6 in spinal cord injuries. Arch. Phys. Med. Rehabil. 78, 44-47
11. Davies, A.L., Hayes, K.C., and Dekaban, G.A. (2007). Clinical correlates of elevated serum concentrations of cytokines, and autoantibodies in patients with spinal cord injury. Arch. Phys. Med. Rehabil. 88, 1384-1393
12. Frost, F., Roach, M.J., Kushner, I., and Schreiber, P. (2005). Inflammatory C-reactive protein, and cytokine levels in asymptomatic people with chronic spinal cord injury. Arch. Phys. Med. Rehabil. 86, 312-317
13. Krishna, V., Andrews, H., Varma, A., Mintzer, J., Kindy, M.S., and Guest, J. (2014). Spinal cord injury: how can we improve the classification, and quantification of its severity, and prognosis? J. Neurotrauma 31, 215-227
14. Wilson, J.R., Grossman, R.G., Frankowski, R.F., Kiss, A., Davis, A.M., Kulkarni, A.V., Harrop, J.S., Aarabi, B., Vaccaro, A., Tator, C.H., Dvorak, M., Shaffrey, C.I., Harkema, S., Guest, J.D., and Fehlings, M.G. (2012). A clinical prediction model for long-term functional outcome after traumatic spinal cord injury based on acute clinical, and imaging factors. J. Neurotrauma 29, 2263-2271
15. Chen, X.L., Sun, L., Guo, F., Wang, F., Liu, S., Liang, X., Wang, R.S., Wang, Y.J., and Sun, Y.X. (2012). High-mobility group box-1 induces proinflammatory cytokines production of Kupffer cells through TLRsdependent signaling pathway after burn injury. PLoS One 7, e50668
16. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J.M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., Manogue, K.R., Faist, E., Abraham, E., Andersson, J., Andersson, U., Molina, P.E., Abumrad, N.N., Sama, A., and Tracey, K.J. (1999). HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251
17. Wang, K.C., Tsai, C.P., Lee, C.L., Chen, S.Y., Chin, L.T., and Chen, S.J. (2012). Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience 226, 510-516
18. Wang, K.Y., Yu, G.F., Zhang, Z.Y., Huang, Q., and Dong, X.Q. (2012). Plasma high-mobility group box 1 levels, and prediction of outcome in patients with traumatic brain injury. Clin. Chim. Acta 413, 1737-1741
19. Yang, H., Antoine, D.J., Andersson, U., and Tracey, K.J. (2013). The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J. Leukoc. Biol. 93, 865-873
20. Lotze, M.T., and Tracey, K.J. (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342
21. Yang, H., Lundback, P., Ottosson, L., Erlandsson-Harris, H., Venereau, E., Bianchi, M.E., Al-Abed, Y., Andersson, U., Tracey, K.J., and Antoine, D.J. (2012). Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18, 250-259
22. Andersson, U., Antoine, D.J, and Tracey, K.J. (2014). The functions of HMGB1 depend on molecular localization, and post-translational modifications. J. Int. Med. 276, 420-424
23. Yang, H., and Tracey, K.J. (2010). Targeting HMGB1 in inflammation. Biochim. Biophys. Acta 1799, 149-156
24. Balosso, S., Liu, J., Bianchi, M.E., and Vezzani, A. (2014). Disulfidecontaining high mobility group box-1 promotes N-methyl-D-aspartate receptor function, and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal neurons. Antioxid. Redox. Signal 21, 1726-1740
25. Maroso, M., Balosso, S., Ravizza, T., Liu, J., Aronica, E., Iyer, A.M., Rossetti, C., Molteni, M., Casalgrandi, M., Manfredi, A.A., Bianchi, M.E., and Vezzani, A. (2010). Toll-like receptor 4, and high-mobility group box-1 are involved in ictogenesis, and can be targeted to reduce seizures. Nat. Med. 16, 413-419
26. Lu, B., Wang, C., Wang, M., Li, W., Chen, F., Tracey, K.J., and Wang, H. (2014). Molecular mechanism, and therapeutic modulation of high mobility group box 1 release, and action: an updated review. Expert Rev. Clin. Immunol. 10, 713-727
27. Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D.J., Cattaneo, A., De Marchis, F., Liu, J., Antonelli, A., Preti, A., Raeli, L., Shams, S.S., Yang, H., Varani, L., Andersson, U., Tracey, K.J., Bachi, A., Uguccioni, M., and Bianchi, M.E. (2012). Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209, 1519-1528
28. Tang, Y., Zhao, X., Antoine, D., Xiao, X., Wang, H., Andersson, U., Billiar, TR., Tracey, K.J., and Lu, B. (2015). Regulation of posttranslational modifications of HMGB1 during immune responses. Antioxid. Redox. Signal 24, 620-634
29. Levy, R.M., Mollen, K.P., Prince, J.M., Kaczorowski, D.J., Vallabhaneni, R., Liu, S., Tracey, K.J., Lotze, M.T., Hackam, D.J., Fink, M.P., Vodovotz, Y., and Billiar, T.R. (2007). Systemic inflammation, and remote organ injury following trauma require HMGB1. American journal of physiology. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R1538-R1544
30. Tsung, A., Tohme, S., and Billiar, T.R. (2014). High-mobility group box-1 in sterile inflammation. J. Int. Med. 276, 425-443
31. Huang, J., Liu, B., Yang, C., Chen, H., Eunice, D., and Yuan, Z. (2013). Acute hyperglycemia worsens ischemic stroke-induced brain damage via high mobility group box-1 in rats. Brain Res. 1535, 148-155
32. Schulze, J., Zierath, D., Tanzi, P., Cain, K., Shibata, D., Dressel, A., and Becker, K. (2013). Severe stroke induces long-lasting alterations of high-mobility group box 1. Stroke 44, 246-248
33. Liesz, A., Dalpke, A., Mracsko, E., Antoine, D.J., Roth, S., Zhou, W., Yang, H., Na, S.Y., Akhisaroglu, M., Fleming, T., Eigenbrod, T., Nawroth, P.P., Tracey, K.J., and Veltkamp, R. (2015). DAMP signaling is a key pathway inducing immune modulation after brain injury. J. Neurosci. 35, 583-598
34. Au, A.K., Aneja, R.K., Bell, M.J., Bayir, H., Feldman, K., Adelson, P.D., Fink, E.L., Kochanek, P.M., and Clark, R.S. (2012). Cerebrospinal fluid levels of high-mobility group box 1, and cytochrome C predict outcome after pediatric traumatic brain injury. J. Neurotrauma 29, 2013-2021
35. Sapojnikova, N., Kartvelishvili, T., Asatiani, N., Zinkevich, V., Kalandadze, I., Gugutsidze, D., Shakarishvili, R., and Tsiskaridze, A. (2014). Correlation between MMP-9, and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome. Biochim. Biophys. Acta 1842, 1379-1384
36. Andersson, A., Covacu, R., Sunnemark, D., Danilov, A.I., Dal Bianco, A., Khademi, M., Wallstrom, E., Lobell, A., Brundin, L., Lassmann, H., and Harris, R.A. (2008). Pivotal advance: HMGB1 expression in active lesions of human, and experimental multiple sclerosis. J. Leukoc. Biol. 84, 1248-1255
37. Wang, H., Wang, K., Wang, C., Xu, F., Zhong, X., Qiu, W., and Hu, X. (2013). Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica, and multiple sclerosis. Neuroimmunomodulation 20, 113-118
38. Malhotra, S., Fissolo, N., Tintore, M., Wing, A.C., Castillo, J., Vidal-Jordana, A., Montalban, X., and Comabella, M. (2015). Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. J. Neuroinflammation 12, 48
39. Wang, Q., Ding, Q., Zhou, Y., Gou, X., Hou, L., Chen, S., Zhu, Z., and Xiong, L. (2009). Ethyl pyruvate attenuates spinal cord ischemic injury with a wide therapeutic window through inhibiting highmobility group box 1 release in rabbits. Anesthesiology 110, 1279-1286
40. Gong, G., Yuan, L.B., Hu, L., Wu, W., Yin, L., Hou, J.L., Liu, Y.H., and Zhou, L.S. (2012). Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines, and HMGB1. Acta Pharmacol. Sin 33, 11-18
41. Kigerl, K.A., Lai, W., Rivest, S., Hart, R.P., Satoskar, A.R., and Popovich, P.G. (2007). Toll-like receptor (TLR)-2, and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. J. Neurochem. 102, 37-50
42. Kigerl, K.A., and Popovich, P.G. (2009). Toll-like receptors in spinal cord injury. Curr. Top. Microbiol. Immunol. 336, 121-136
43. Didangelos, A., Puglia, M., Iberl, M., Sanchez-Bellot, C., Roschitzki, B., and Bradbury, E.J. (2016). High-throughput proteomics reveal alarmins as amplifiers of tissue pathology, and inflammation after spinal cord injury. Sci. Rep. 6, 21607
44. Yang, J., Liu, X., Zhou, Y., Wang, G., Gao, C., and Su, Q. (2013). Hyperbaric oxygen alleviates experimental (spinal cord) injury by downregulating HMGB1/NF-kappaB expression. Spine (Phila Pa 1976) 38, E1641-E1648
45. Cohen, M.J., Brohi, K., Calfee, C.S., Rahn, P., Chesebro, B.B., Christiaans, S.C., Carles, M., Howard, M., and Pittet, J.F. (2009). Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity, and tissue hypoperfusion. Crit. Care 13, R174
46. Sokol, B., Wozniak, A., Jankowski, R., Jurga, S., Wasik, N., Shahid, H., and Grzeskowiak, B. (2015). HMGB1 level in cerebrospinal fluid as a marker of treatment outcome in patients with acute hydrocephalus following aneurysmal subarachnoid hemorrhage. J. Stroke Cerebrovasc. Dis. 24, 1897-1904
47. Casula, M., Iyer, A.M., Spliet, W.G., Anink, J.J., Steentjes, K., Sta, M., Troost, D., and Aronica, E. (2011). Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 179, 233-243
48. Juranek, J.K., Daffu, G.K., Wojtkiewicz, J., Lacomis, D., Kofler, J., and Schmidt, A.M. (2015). Receptor for advanced glycation end products, and its inflammatory ligands are upregulated in amyotrophic lateral sclerosis. Front. Cell Neurosci. 9, 485
49. Kawabata, H., Setoguchi, T., Yone, K., Souda, M., Yoshida, H., Kawahara, K., Maruyama, I., and Komiya, S. (2010). High mobility group box 1 is upregulated after spinal cord injury, and is associated with neuronal cell apoptosis. Spine (Phila Pa 1976) 35, 1109-1115
50. Kikuchi, K., Uchikado, H., Miura, N., Morimoto, Y., Ito, T., Tancharoen, S., Miyata, K., Sakamoto, R., Kikuchi, C., Lida, N., Shiomi, N., Kuramoto, T., Miaygi, N., and Kawahara, K. (2011). HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development. Exp. Ther. Med. 2, 767-770
51. Guo, J.D., Li, L., Shi, Y.M., Wang, H.D., Yuan, Y.L., Shi, X.X., and Hou, S.X. (2014). Genetic ablation of receptor for advanced glycation end products promotes functional recovery in mouse model of spinal cord injury. Mol. Cell. Biochem. 390, 215-223
52. Zhai, C.L., Zhang, M.Q., Zhang, Y., Xu, H.X., Wang, J.M., An, G.P., Wang, Y.Y., and Li, L. (2012). Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacol. Sin. 33, 1477-1487
53. Yang, H., Pellegrini, L., Napolitano, A., Giorgi, C., Jube, S., Preti, A., Jennings, C.J., De Marchis, F., Flores, E.G., Larson, D., Pagano, I., Tanji, M., Powers, A., Kanodia, S., Gaudino, G., Pastorino, S., Pass, H.I., Pinton, P., Bianchi, M.E., and Carbone, M. (2015). Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell. Death Dis 6, e1786
54. Sundberg, E., Grundtman, C., Af Klint, E., Lindberg, J., Ernestam, S., Ulfgren, A.K., Harris, H.E., and Andersson, U. (2008). Systemic TNF blockade does not modulate synovial expression of the proinflammatory mediator HMGB1 in rheumatoid arthritis patients-a prospective clinical study. Arthritis Res. Ther. 10, R33
55. Allette, Y.M., Due, M.R., Wilson, S.M., Feldman, P., Ripsch, M.S., Khanna, R., and White, F.A. (2014). Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain. Brain Behav. Immun. 42, 169-177
56. Feldman, P., Due, M.R., Ripsch, M.S., Khanna, R., and White, F.A. (2012). The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain. J. Neuroinflammation 9, 180